BioRestorative Therapies, Inc. BRTX
used in this Annual Report on Form 10-K, or the Annual Report, references to the "Company", "we", "us",
or "our" refer to BioRestorative Therapies, Inc.
"BioRestorative Therapies, Inc." Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we
reincorporated in Nevada.
Last close
0.15
2026-09-04
Market cap
$3.8M
2026-03-31 share count
52-week range
0.14 - 1.73
Valuation FY2025 figures against the last close
P/S10.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.58
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K | $77.0K | $130.0K | $111.0K | $81.0K | $36.4K |
| Cost of revenue | $23.8K | $28.1K | — | — | — | — | — | — | — | $102 |
| Gross profit | $335.9K | $372.9K | $145.8K | — | — | — | — | — | $81.0K | $36.3K |
| R&D | $10.1M | $6.7M | $4.0M | $3.5M | $729.1K | $876.8K | $1.7M | $1.5M | $2.2M | $2.9M |
| SG&A | $5.9M | $5.2M | $11.3M | $15.6M | $25.6M | $1.8M | $4.6M | $4.0M | $3.9M | $3.2M |
| Total operating expenses | $16.0M | $11.9M | $15.4M | $19.1M | $26.4M | $2.8M | $8.6M | $7.8M | $8.5M | $7.8M |
| Operating income | -$15.6M | -$11.6M | -$15.2M | -$19.0M | -$26.3M | -$2.8M | -$8.4M | -$7.6M | -$8.4M | -$7.8M |
| Interest expense | $266.2K | $616.1K | $552.3K | $11.7K | $1.8M | — | — | — | — | — |
| Pre-tax income | -$14.2M | -$9.0M | — | — | — | — | — | — | -$9.4M | -$8.6M |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$13.2M | -$44.3M | -$11.3M | -$14.6M | -$12.5M | -$9.4M | -$8.6M |
| EPS, basic | -1.58 | -1.16 | -2.47 | -3.65 | -37.30 | — | — | — | — | — |
| EPS, diluted | -1.58 | -1.16 | -2.47 | -3.65 | -37.30 | -28.56 | -0.66 | -1.64 | -1.74 | -2.10 |
| Shares, diluted (wtd. avg.) | $9.0M | $7.8M | $4.2M | $3.6M | $1.2M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.5M | $547.9K | $884.4K | $1.7M | $21.0M | — | — | — | — | — |
| Short-term investments | $1.4M | $10.2M | $10.2M | $13.0M | — | — | — | — | — | — |
| Receivables | $15.5K | $188.4K | $19.3K | $16.0K | $5.0K | $17.0K | $32.0K | $29.0K | $38.0K | $6.0K |
| Total current assets | $3.1M | $11.1M | $11.4M | $15.1M | $21.5M | $3.2M | $68.9K | $181.0K | $519.7K | $73.4K |
| Property, plant and equipment | $358.8K | $362.9K | $356.1K | $261.0K | $38.0K | $21.9K | $68.4K | $175.2K | $327.8K | $508.6K |
| Other intangibles | $534.2K | $623.9K | $713.7K | $803.4K | $589.7K | $664.3K | $739.2K | $814.1K | $889.0K | $963.8K |
| Total assets | $4.1M | $12.3M | $12.6M | $16.4M | $22.5M | $4.3M | $1.5M | $1.2M | $1.8M | $1.6M |
| Accounts payable | $1.3M | $483.1K | $189.4K | $170.9K | $50.8K | $118.9K | $2.0M | $1.9M | $2.5M | $2.3M |
| Total current liabilities | $3.7M | $3.7M | $2.6M | $7.1M | $14.7M | $1.0M | $13.7M | $9.3M | $8.4M | $5.8M |
| Long-term debt | — | — | — | — | $250.0K | — | — | — | — | — |
| Total liabilities | — | $3.7M | $2.6M | $7.3M | $15.0M | $5.7M | $14.2M | $9.8M | $8.6M | $6.6M |
| Retained earnings | -$169.9M | -$155.7M | -$146.7M | -$128.2M | -$131.3M | -$89.8M | -$78.6M | -$63.9M | -$51.4M | -$42.0M |
| Total equity | $356.7K | $8.5M | $10.0M | $10.3M | $10.8M | -$1.3M | -$12.8M | -$8.6M | -$6.8M | -$5.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$8.2M | -$6.4M | -$5.9M | -$3.3M | -$2.0M | -$6.9M | -$5.1M | -$3.9M | -$5.0M |
| Depreciation and amortisation | $120.2K | $99.3K | $76.0K | $42.2K | $89.1K | $121.4K | $217.4K | $240.4K | $259.3K | $258.4K |
| Stock-based compensation | $3.3M | $2.8M | $7.8M | $12.6M | $23.1M | $691.7K | $1.7M | $2.4M | $3.6M | $2.5M |
| Capital expenditure | $116.1K | $106.2K | $171.0K | $265.2K | $30.7K | — | $35.6K | $12.9K | $3.6K | $188.8K |
| Investing cash flow | $8.9M | $514.5K | $3.3M | -$13.4M | -$30.7K | — | -$35.6K | -$12.9K | -$3.6K | -$188.8K |
| Financing cash flow | $2.9M | $7.4M | $2.3M | — | $21.3M | $5.0M | $6.8M | $4.8M | $4.3M | $5.1M |
| Buybacks | $0 | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012925.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.74B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.39B | 70.0x | 5.7% |
| PGNY | Progyny, Inc. | $1.99B | 39.9x | 10.4% |
| AGL | agilon health, inc. | $1.49B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $345.8M | 24.5x | 20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | $34.5M | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | $8.9M | — | -26.0% |
| FMS | Fresenius Medical Care AG | — | — | — |